PROBLEM TO BE SOLVED: To provide a novel target for production of immune and non-immune based therapeutics and for disease diagnosis.SOLUTION: The invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.SELECTED DRAWING: Figure 1COPYRIGHT: (C)2016,JPO&INPIT【課題】免疫および非免疫ベースの治療薬の生産並びに疾患診断のための新規の標的に関する。【解決手段】共刺激ファミリーメンバーと予想され、肺癌、卵巣癌および結腸癌を含む癌に差次的に発現されるVSIG1、ILDR1、LOC253012、AI216611、C1ORF32またはFXYD3抗原に対する治療抗体、並びに診断および治療の用途を提供する。B7共刺激を調節するため、自己免疫の治療などの関連する治療のための、これら抗体の利用。さらに、免疫療法、癌治療、および薬剤開発のための適切な標的である、VSIG1およびその変異体、FXYD3およびその変異体、ILDR1およびその変異体、LOC253012およびその変異体、AI216611およびその変異体、並びにC1ORF32およびその変異体の細胞外領域の発見に関する。【選択図】図1
